How long does 6-APDB last?

The total duration of 6-APDB via oral is 6 hours to 8 hours. Onset typically occurs within 30 minutes to 1 hour. Peak effects last 2 hours to 3 hours.

6-APDB — SubstanceWiki

6-APDB (6-(2-aminopropyl)-2,3-dihydrobenzofuran), also known as 4-desoxy-MDA or 3-desoxy-MDA, is a substituted benzofuran entactogen closely related to MDA and to the APB series. The "6" position isomer has been the primary focus of research, though 4-APDB and 5-APDB also exist. Unlike 5-APB and 5-MAPB which feature an unsaturated benzofuran ring, 6-APDB contains a dihydrobenzofuran scaffold — structurally very close to MDA with the oxygen of the methylenedioxy bridge replaced by a single methylene oxygen in a 2,3-dihydrobenzofuran ring.

The experiential profile is described as strongly empathogenic with significant stimulant character, closely resembling MDA but with somewhat less psychedelic visual intensity and a longer duration than MDMA. It emerged in the novel psychoactive substance market alongside the APB series and carries the same range of serotonergic risks — neurotoxicity potential, cardiovascular strain, and cardiac 5-HT2B agonism with repeated use.

How It Feels

The onset of 6-APDB is gradual and understated. An hour to ninety minutes after ingestion, a faint warmth begins to gather in the chest. Emotional registers soften subtly, and there is a growing sense of ease and openness that arrives without fanfare. The body relaxes gently, tension releasing from the shoulders and jaw. Unlike its more forceful relatives, 6-APDB does not announce itself with euphoric waves or dramatic perceptual shifts. Instead, it quietly adjusts the emotional thermostat upward by a few degrees.

As the effects develop, a mild empathogenic quality establishes itself. Social interactions feel slightly warmer and more genuine. There is an increased willingness to listen, to empathize, and to share, but these qualities feel like enhancements of existing tendencies rather than departures from normal behavior. Touch sensitivity increases modestly, and music takes on a subtle emotional richness. The stimulant component is minimal to absent; the body feels relaxed and comfortable rather than energized. There is little desire to dance or move vigorously, and the experience favors quiet intimacy over active socializing.

At the peak, roughly two to three hours in, 6-APDB maintains its characteristic restraint. The emotional warmth is genuine but mild, a pleasant glow rather than an overwhelming flood. There may be subtle visual changes: slightly enhanced color saturation, a gentle softening of edges. The headspace is calm and clear, undisturbed by the cognitive disruption that accompanies stronger empathogenic compounds. Physical side effects are minimal: modest jaw tension, slight pupil dilation, mild warmth. The experience is comfortable and benign, well-suited to reflective conversation or simply sitting with another person in companionable warmth.

The decline begins around four to five hours in and is as gentle as the onset. The mild warmth gradually recedes, and baseline emotional functioning returns without any jarring transition. The comedown is notably mild compared to stronger empathogenic compounds. There may be slight fatigue and a touch of emotional quietness the following day, but the serotonergic debt is small, proportional to the modest effects that generated it. The total duration of five to seven hours passes comfortably, and the experience is often described as pleasant, gentle, and somewhat forgettable, a mild exploration of warmth without the costs that usually accompany it.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(12)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(8)

Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
Settings, sceneries, and landscapes

Detection Methods

Standard Drug Panel Inclusion

6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) is a benzofuran-class entactogen that is not detected on standard 5-panel or 10-panel immunoassay drug screens. Some MDMA/amphetamine immunoassays may show partial cross-reactivity due to the aminopropyl side chain, but this varies by manufacturer and cannot be relied upon. Extended panels do not typically include benzofuran compounds.

Urine Detection

6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) can be detected in urine for approximately 2 to 4 days after use. Metabolism involves hepatic oxidation, O-dealkylation, and conjugation. The metabolic pathway has some overlap with MDMA metabolism due to the structural analogy, but the benzofuran ring system produces distinct metabolites. Standard immunoassay screens are unreliable for detecting benzofuran compounds.

Blood and Saliva Detection

Blood detection windows for 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) are approximately 12 to 48 hours. Oral fluid detection is possible for 24 to 48 hours. These modalities are used primarily in emergency medicine and forensic toxicology settings rather than routine drug testing.

Hair Follicle Detection

Hair follicle testing for 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) requires specialized LC-MS/MS analysis and is not included in standard commercial hair testing panels. Detection in hair is possible for up to 90 days with appropriate analytical methods and reference standards.

Confirmatory Testing

LC-MS/MS is the gold standard for confirming the presence of 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran). This method can distinguish benzofuran compounds from MDMA, MDA, and other entactogens based on molecular weight, fragmentation patterns, and retention time. GC-MS is also effective. Reference standards are essential for positive identification.

Reagent Testing

Marquis reagent typically produces a dark purple to black color with 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran), similar to the reaction seen with MDMA and MDA (due to the oxygen-containing ring system). Mecke reagent produces a blue-green to dark blue reaction. Simon's reagent helps differentiate primary amines (5-APB, 6-APDB: negative) from secondary amines (5-MAPB: positive). Mandelin may show an orange-brown color. The combination of reagent responses can narrow identification but cannot conclusively distinguish benzofurans from methylenedioxy compounds.

Interactions

Substance	Status	Note
25x-NBOH	Dangerous	—
25x-NBOMe	Dangerous	—
Atropa belladonna	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Datura	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Diphenhydramine	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Harmala alkaloid	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Peganum harmala	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
MDMA	Unsafe	—
1,3-Butanediol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
25E-NBOH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-2	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-21	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-7	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increased cardiovascular strain and neurotoxicity risk
4-MMC	Caution	Increased cardiovascular strain and neurotoxicity risk
8-Chlorotheophylline	Caution	Increased cardiovascular strain and neurotoxicity risk
Adrafinil	Caution	Increased cardiovascular strain and neurotoxicity risk
Allylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ayahuasca	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Benzydamine	Caution	Increased cardiovascular strain and neurotoxicity risk
Bromantane	Caution	Increased cardiovascular strain and neurotoxicity risk
Cake	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Deschloroetizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Desomorphine	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
DET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increased cardiovascular strain and neurotoxicity risk
Diclazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
DiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DOM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Efavirenz	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephedrine	Caution	Increased cardiovascular strain and neurotoxicity risk
EPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Eszopiclone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Etizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Gaboxadol	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Hexedrone	Caution	Increased cardiovascular strain and neurotoxicity risk
Ibogaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lorazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Mephenaqualone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methallylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increased cardiovascular strain and neurotoxicity risk
Metizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Midazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Naloxone	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
Nicotine	Caution	Increased cardiovascular strain and neurotoxicity risk
Nifoxipam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Oxiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Pentobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenylpiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Psilocybin Mushrooms	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increased cardiovascular strain and neurotoxicity risk
SAMe	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Alcohol	Uncertain	—

Showing 63 key interactions out of 64 total.

Toxicity & Safety

Acute Toxicity

As a serotonin-releasing amphetamine-class compound, 6-APDB's acute risks parallel those of MDA: hyperthermia, hyponatremia, serotonin syndrome, and cardiovascular strain. Hyperthermia is the most immediately life-threatening acute event, particularly in warm or physically active settings.

Neurotoxicity

6-APDB's structural analogy to MDA — the most robustly neurotoxic ring-substituted amphetamine in animal models — raises significant concern about serotonergic axon terminal damage with repeated use. The mechanism involves reactive quinone metabolites generated by CYP450 N-demethylation and ring oxidation that produce oxidative damage to the serotonin system. Hyperthermia dramatically amplifies this toxicity.

Cardiovascular Risks

Norepinephrine and dopamine release produce elevated heart rate and blood pressure. Combined with any direct 5-HT2B agonism, chronic use poses both acute cardiovascular strain and potential long-term valvular risks.

Contraindications

MAOIs — absolute contraindication (serotonin syndrome)
Structural cardiac disease, hypertension, or arrhythmias
Personal or family history of psychosis or mania

Addiction Potential

moderately addictive with a high potential for abuse

Overdose Information

Stimulant overdose from 6-APDB is a medical emergency primarily involving cardiovascular and neurological toxicity.

Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.Emergency response:

Call emergency services immediately
Keep the person cool (remove excess clothing, apply cool water)
If seizures occur, protect the head and clear the area of hard objects
If the person loses consciousness, place in recovery position
Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionalsPrevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.

Full	with prolonged and repeated use
Half	21-30 days
Zero	2-3 months

6-APDB

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(12)

Tactile(1)

Cognitive & Perceptual Effects

Visual(8)

Pharmacology

Mechanism of Action

Structural Relationship to MDA

Pharmacokinetics

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Saliva Detection

Hair Follicle Detection

Confirmatory Testing

Reagent Testing

Interactions

History

Development

Market Appearance

Legal Status

Harm Reduction

Reagent Testing

Dose and Timing

Neurotoxicity Risk Reduction

Dangerous Combinations

Toxicity & Safety

Acute Toxicity

Neurotoxicity

Cardiovascular Risks

Contraindications

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (3)

See Also

References (6)

Frequently Asked Questions

Cognitive(17)

Transpersonal(2)